Abstract: This invention relates to compounds having the following formula ##STR1## or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions including the compounds, and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

Abstract: A derivative of general formula: ##STR1## wherein Y is --SO.sub.2 -- or ##STR2## (i) R.sup.1 and R.sup.2, which may the same or different, each represent, (1) --H, (2) C1-16 alkyl or (3) the formula: --X--A-- (R.sup.4)n wherein X is single-bond, --SO.sub.2 --, C1-4 alkylene, C1-4 alkylene substituted by --COOH or ##STR3## --A-- is a pyridyl or pyrrolyl ring, n is 1.about.5, R.sup.4 is 1 --H or C1-8 alkyl, 2 C1-14 alkoxy, 3 C1-6 alkylthio, 4 --OH, halogen, --NO.sub.2 or trihalomethyl, 5 the formula: --NR.sup.41 R.sup.42 wherein R.sup.41 and R.sup.42 each represents halogen or C1-4 alkyl, 6 tetrazole, 7 --SO.sub.3 H or --CH.sub.2 OH, 8 the formula: --SO.sub.2 NR.sup.41 R.sup.42 9 the formula: --Z.sup.41 --COOR.sup.43 wherein Z.sup.41 is single-bond, C1-4 alkylene or C2-4 alkenylene, R.sup.

Abstract: Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

Abstract: Amides having formula I: ##STR1## wherein E, X, R.sup.2 and R.sup.3 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof, which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the amides and pharmaceutical compositions containing them.

Abstract: This invention relates to compounds having the following formula ##STR1## or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions including the compounds and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

Abstract: The invention relates to compounds of the formula I ##STR1## in which A represents a substituted thio-, sulfinyl- or sulfonyl-alkanoyl radical or a four- to eleven-membered heterocycle, B is an amino acid residue, R.sup.1 denotes hydrogen (substituted) alkyl, (substituted)cycloalkyl or aryl, R.sup.2 represents hydrogen, (substituted)alkyl or aryl, R.sup.3 denotes a radical of the formula --(CH.sub.2).sub.q --(X).sub.r --(CH.sub.2).sub.s --R.sup.6 with X denoting CF.sub.2, CO or CHR.sup.8, R.sup.6 denoting a (substituted)heteroaromatic, R.sup.8 denoting alkyl, alkoxy, alkylthio, alkylamino, hydroxyl, azide or halogen, q and s denoting 1 to 4, and r denoting 0 or 1, and R.sup.9 is hydrogen, (substituted)alkyl, alkanoyl, cycloalkanoyl, (substituted) aroyl or (substituted)aryl, and to the salts thereof. In addition, processes for the preparation of these compounds, and the use thereof as renin inhibitors are described.

Abstract: The invention concerns pharmaceutically useful novel compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

Abstract: The present invention provides novel N-substituted hydrazine bifunctional compounds, novel N-subhstituted hydrazone derivatives of a cytotoxic reagent incorporating the bifunctional compounds, novel conjugates containing at least one cytotoxic reagent molecule reacted with the bifunctional compound and bound to a molecule reactive with a target cell population, methods for their production, and pharmaceutical compositions and methods for delivering cytotoxic reagents to a target population of cells. The hydrazone bonds of the conjugates of the invention permit the release of free cytotoxic reagent from the conjugates in the acidic external or internal environment of the target cells. The bifunctional compounds, derivatives, conjugates and methods of the invention are useful in antibody-or ligand-mediated drug delivery systems for the perferential killing of a target cell population to treat diseases such as cancers, infections and autoimmune disorders.

Abstract: The invention provides insecticidally active compounds of formula (I): ##STR1## wherein X is nitrogen or carbon bearing a hydrogen atom; R.sup.1 is a group of formula --S(O).sub.n --Y, wherein Y is an optionally substituted heterocyclic ring containing at least one nitrogen atom, the point of attachment of the group Y being at a ring nitrogen atom, and n is 0, 1 or 2; R.sup.2 is a group of formula --OSO.sub.2 R.sup.3 wherein R.sup.3 is selected from C.sub.1-8 alkyl, C.sub.1-4 alkyl substituted by an optionally substituted phenyl or heterocyclic ring, C.sub.1-8 haloalkyl, C.sub.2-6 alkenyl, C.sub.2-4 alkenyl substituted by an optionally substituted phenyl or heterocyclic ring, C.sub.2-4 alkynyl, C.sub.2-4 alkynyl substituted by an optionally substituted phenyl or heterocyclic ring, optionally substituted aryl, and a group of formula --N(R.sup.4)(R.sup.5) wherein R.sup.4 and R.sup.5 are independently selected from hydrogen and C.sub.1-6 alkyl or wherein R.sup.4 and R.sup.5 together represent --(CH.sub.2).sub.

Abstract: New tetralin derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 and Z have the meanings indicated herein and salts thereof, exhibit an effect on the cardiovascular system.

Abstract: Topical polyethylene glycol based formulations for the delivery of 2-substituted-1-naphthols and indoles and particularly, 2-phenylmethyl-1-naphthol are provided. Said topical formulations exert excellent localized antiinflammatory activity while demonstrating low levels of skin penetration in vitro and in vivo thereby reducing unwanted side effects and reducing systemic toxicity associated with the active drug compounds.

Abstract: The invention relates to the products of formula ##STR1## in which R represents the radical ##STR2## in which R.sub.1 at any position on the benzene ring represents linear, branched or cyclic alkyl, alkenyl or alkynyl containing up to 8 carbon atoms, or the radical ##STR3## in which R.sub.2 and R.sub.3, which may be identical or different, represents hydrogen or linear alkyl, alkenyl or alkynyl containing up to 8 carbon atoms or form, together with the nitrogen atom to which they are attached, a carbonaceous heterocyclic radical optionally containing another hetero atom, or the radical OR', R' representing hydrogen, a linear, branched or cyclic alkyl containing up to 8 carbon atoms or aryl containing up to 14 carbon atoms, or the radical SR.sub.4 or S(O)R.sub.5, R.sub.4 and R.sub.5 representing linear, branched or cyclic alkyl, alkenyl, or alkynyl containing up to 8 carbon atoms, or R represents naphthyl optionally substituted with the radical R'.sub.1, R'.sub.1 being as defined above for R.sub.

Abstract: A compound of the formula ##STR1## wherein X has the formula ##STR2## wherein ring a is phenyl, naphthyl or heterocyclic; wherein R.sup.1 is hydrogen, alkyl, alkanoyl or aroyl; wherein R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, each is an electron withdrawing substituent selected from halogeno, nitro, cyano, trifluoromethyl, alkylthio, alkylsulphinyl, and alkylsulphonyl or each is hydrogen, alkyl, alkoxy or dialkylamino provided that when ring A is phenyl or naphthyl at least one of R.sup.2, R.sup.3 and R.sup.4 is an electron-withdrawing substituent; wherein R.sup.5 and R.sup.6, which may be the same or different, each is hydrogen, halogeno or alkyl; wherein R.sup.7 is alkyl or halogenoalkyl; and wherein R.sup.8 is carbamoyl, alkyl, cycloalkyl, alkenyl, alkynyl, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkanoyl, alkylcarbamoyl, dialkylcarbamoyl or aroyl; or wherein R.sup.

Abstract: Disclosed are the compounds of formula ##STR1## wherein A represents lower alkylene; B represents oxygen, sulfur, lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl-, sulfonyl- or thio)-lower alkylene, lower alkenylene, phenylene or a direct bond; M represents lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl, sulfonyl- or thio)-lower alkylene, lower alkenylene or a direct bond; or one of A, B and M represents lower alkylidenylene and the other two independently represent lower alkylene; R represents hydrogen unless A, B or M represents lower alkylidenylene in which case R represents the second bond to the adjacent aklylidenylene unsaturated carbon atom; Het represents 1-imidazolyl, 3-pyridyl, or 1-imidazolyl or 3-pyridyl substituted by lower alkyl; Ar represents carbocyclic or heterocyclic aryl; pharmaceutically acceptable ester and amide derivatives thereof; the N-oxides of said compounds wherein Het represent

Abstract: Novel tricyclic compounds having a TXA.sub.2 -antagonizing activity represented by formula (I): ##STR1## which strongly antagonize an action of thromboxane A.sub.2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.

Abstract: Fungicidal pyridyl-substituted acrylic esters of the formula ##STR1## in which R.sup.1 represents alkyl or represents optionally substituted aralkyl,R.sup.2 represents dialkylamino or represents a radical --Z--R.sup.3,X represents oxygen or sulphur or represents a radical ##STR2## Py represents optionally substituted pyridyl, where R.sup.3 represents alkyl or represents optionally substituted aralkyl,R.sup.4 represents hydrogen, alkyl or alkanoyl or represents in each case optionally substituted aralkyl or aryl andZ represents oxygen or sulphur, their geometric isomers and isomer mixtures.

Abstract: Compounds having the formula: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

Abstract: Insecticidal compounds having the formula ##STR1## in which R is an optionally substituted aryl moiety; R.sub.2 is an optionally substituted alkyl, cycloalkyl or alkenyl moiety, X is sulfur, amino or C.sub.1 -C.sub.4 monoalkylamino; and R.sub.3 is: (a) an optionally substituted 3-phenoxyphenalkyl, 3-phenoxypyridylalkyl or 3-(4-pyridyloxy)phenalkyl moiety; (b) pentafluorobenzyl; or (c) 2-methyl-3-phenylbenzyl.

Abstract: Disclosed herein is a compound of the formula: ##STR1## wherein Ar is pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, isoquinoline ring or thiazole ring, and those rings may be substituted by 1.about.3 of substituents selected from the group consisting of halogen, C.sub. 1 .about.C.sub.4 -alkyl, C.sub.1 .about.C.sub.4 -alkoxy, CF.sub.3 and nitro,R.sup.1 is C.sub.1 .about.C.sub.8 -alkyl; C.sub.1 .about.C.sub.7 -alkyl which is substituted by 1.about.3 of F, Cl or Br, C.sub.1 .about.C.sub.4 -alkoxy or C.sub.1 .about.C.sub.4 -alkylthio; C.sub.3 .about.C.sub.7 -cycloalkyl which may be substituted by 1.about.4 of F, Cl or methyl; C.sub.3 .about.C.sub.6 -cycloalkylmethyl which may be substituted by 1.about.4 of F, Cl, Br or methyl; allyl, propargyl, phenyl or benzyl; R.sup.2 is C.sub.1 .about.C.sub.4 -alkyl which may be substituted by 1.about.3 of F or Cl,x is integer of 0, 1 or 2, excepting wherein Ar is pyridine ring which is substituted by R.sup.1 --S(O)x and --O--SO.sub.2 R.sup.

Abstract: Heterocyclic compounds of the formula ##STR1## wherein X is --CH.dbd.CH--; R.sup.1 is the group Ar--R.sup.2 or --CH.dbd.CH--C(CH.sub.3).dbd.CH--R.sup.21 ; Ar is phenyl, pyridyl, furyl or thienyl; R.sup.2 is --CO.sub.2 R.sup.3, --C(O)R.sup.4, --CH.sub.2 OR.sup.3, lower-alkylsulphonyl or formyl; R.sup.21 is --CO.sub.2 R.sup.3, --C(O)R.sup.4, --CH.sub.2 OR.sup.3 or formyl; R.sup.3 is hydrogen or lower-alkyl; and R.sup.4 is hydrogen, hydroxy, amino, lower-alkyl amino, di-(lower alkyl)amino or lower alkyl; with at least one ring of the molecule being heterocyclic, as well as salts of such compounds are useful in rodenticidal compositions containing a bait to eliminate rodents.

Abstract: Compounds of formula (I) ##STR1## wherein X and Y each represent a bond or an alkylene, alkenylene or alkynylene chain;R.sup.1 and R.sup.2 each represent a hydrogen atom or a lower alkyl group; andPy represents a pyridyl group having one or two substituents. The compounds have a stimulant action at beta.sub.2 -adrenoreceptors. The compounds may be used in the treatment of diseases associated with reversible airway obstruction such as asthma and chronic bronchitis.

Abstract: There are disclosed novel 1-nitro-2,2-diaminoethylene derivatives of formula I ##STR1## wherein X is chlorine, fluorine, unsubstituted or halogen-substituted C.sub.1 -C.sub.5 alkyl; unsubstituted or halogen-substituted C.sub.1 -C.sub.5 alkoxy, unsubstituted or halogen-substituted C.sub.1 -C.sub.5 akylthio, unsubstituted or halogen-substituted alkylsulfinyl, unsubstituted or halogen-substituted alkylsulfonyl; or also nitro, cyano, thiocyanato, C.sub.3 -C.sub.5 haloalkenyl, C.sub.3 -C.sub.5 haloalkynyl, hydroxy, C.sub.1 -C.sub.5 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 dialkylamino, C.sub.1 -C.sub.5 alkylcarbonyl, C.sub.1 -C.sub.5 alkylcarbamoyl or C.sub.1 -C.sub.5 alkylcarbonyloxy,n is an integer from 0 to 4,R.sub.1 is hydrogen, C.sub.1 -C.sub.5 alkyl or C.sub.3 -C.sub.7 cycloalkyl,R.sub.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.3 -C.sub.7 cycloalkyl,R.sub.3 is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.3 -C.sub.7 cycloalkyl, benzyl or pyridinylmethyl, or R.sub.2 and R.sub.

Abstract: Novel arylsulfonyl-dihydropyridine derivatives which are useful as calcium entry-blocker cardiovascular agents have the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyalkyl;R.sup.2 is hydrogen or chloro; andR.sup.3 is hydrogen, lower alkyl, or lower alkoxyethyl.A novel process using chiral sulfoxide reagents efficiently produces single isomers of these and other sulfonyl dihydropyridines.

Abstract: Acrylic acid derivatives of the formula: ##STR1## an stereoisomers thereof wherein W is pyridyl or pyrimidinyl, A is oxygen or S(O).sub.n where n is 0, 1 or 2; X, Y and X are, for example, hydrogen, halogen, hydroxy or optionally substituted alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy or aralkyl among other possible values; R.sup.1 and R.sup.2 are optionally substituted alkyl, and metal complexes thereof. The compounds are useful fungicides.

Abstract: New substituted derivatives of 1,2,6-triphenyl-4(1H)-pyridone are now provided, which are useful as fungicidal agent having practically valuable and improved fungicidal activities against a variety of phyto-pathogenic microorganisms, especially fungi and which show low toxicity to animals, including humans. These new compounds may be produced by different processes.

Abstract: Pyridine derivatives of the formula ##STR1## their tautomers and their salts, in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and n have the meanings given in the claims, can be used as active ingredients in medicaments and are manufactured in a manner known per se.

Abstract: The present invention provides an aqueous, alkaline injection solution of torasemide ready for injection, which contains a physiologically compatible alkaline buffer with a pH value of from 9.3 to 9.9 and with a buffer capacity of up to 0.1 val/liter together with an organic solvent in an amount of from 5 to 20% by weight selected from the group of polyethylene glycols with a molecular weight of from 100 to 1500, polypropylene glycols with a molecular weight of from 50 to 1000, glycerol, propylene glycol, ethanol and propanol, the torasemide being present in a concentration of from 2 to 40 mg/ml. Torasemide solutions are useful to inhibit inflammation or promote diuresis.The present invention also provides a process for the preparation of this solution, wherein torasemide is suspended in the above organic solvent brought into solution by the addition of aqueous alkali, adding the buffer and other adjuvants and adjusting the pH value to 9.3 to 9.9.

Abstract: Dihydropyridine derivatives of the formula ##STR1## wherein the symbols R and R.sup.1 to R.sup.6 have the significance given in claim 1, have a pronounced calcium-antagonist activity and can accordingly be used as medicaments, especially in the control or prevention of angina pectoris, ischemia, high blood pressure and/or migraine.

Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrines of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic and anti-inflammatory agents.

Abstract: The present invention provides a process for the preparation of cystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, melting point 162.degree. C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169.degree. C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.The present invention also provides pharmaceutical compositions containing torasemide of modification I.

Abstract: Novel adducts of menadione with pyridine derivatives, said compounds having vitamin B.sub.6 activity and vitamin K activity, and being useful in animal feed premix and animal feed compositions.

Abstract: There are provided new alkane and alkoxyalkane derivatives of the general formula I ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A have the meanings given in the description, processes for their preparation and insecticidal and acaricidal compositions containing these compounds.

Abstract: New substituted derivatives of 1,2,6-triphenyl-4(1H)-pyridinone are now provided, which are useful as fungicidal agent having practically valuable and improved fungicidal activities against a variety of phyto-pathogenic microorganisms, especially fungi and which show low toxicity to animals, including humans. These new compounds may be produced by different processes.

Abstract: The present invention relates to the use of secondary 2-aminoalkyl-5-pyridinols of the general formula I ##STR1## wherein R is hydrogen or lower alkyl, m is an integer from 2 to 4 and n is an integer from 1 to 7, and the acid addition salts thereof, as nootropic agents and antidepressants and for the preparation of pharmaceutical compositions having nootropic and antidepressant activity.

Abstract: The invention relates to new aromatic alkane derivatives of the general formula ##STR1## in which R.sub.1 is aryl or aryl substituted by C.sub.1-4 alkyl, halo-C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl, C.sub.2-4 alkenyl, halo-C.sub.2-4 alkenyl, phenyl-C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, halo-C.sub.2-4 alkynyl, phenyl-C.sub.2-4 alkynyl, C.sub.1-4 alkoxy, halo-C.sub.1-4 alkoxy, phenyl-C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, halo-C.sub.2-4 alkenyloxy, phenyl-C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, halo-C.sub.2-4 alkynyloxy, phenyl-C.sub.2-4 alkynyloxy, alkylsulphonyloxy, haloalkylsulphonyloxy, arylsulphonyloxy, halo, cyano, nitro, aryloxy, haloaryloxy, C.sub.1-4 alkyl-aryloxy, or nitroaryloxy,R.sub.2 is hydrogen or C.sub.1-4 alkyl,R.sub.3 is hydrogen, cyano or ethynyl,R.sub.4 is phenyl or pyridyl or these groups substituted by one or more of C.sub.1-6 alkyl, halo-C.sub.1-6 alkyl, phenyl-C.sub.1-6 alkyl, C.sub.1-6 alkyl interrupted by an O-, N- or S- atom, C.sub.2-4 alkenyl, halo-C.sub.2-4 alkenyl, phenyl-C.

Abstract: The present invention is related to new S-(Carbamoyl-phenylselenyl) derivatives of mercaptanes of the general formula (I) ##STR1## and to a process for the treatment of diseases caused by cell injury due to the increased formation of active oxygen metabolites.

Abstract: Acetylenes of the following formula (I): ##STR1## wherein Y, m, R.sup.1, R.sup.2, R.sup.3, n and R.sup.4 are defined herein and R.sup.5 is hydrogen, alkyl, cycloalkyl or substituted alkyl are useful vasodilators and antihypertensives.

Abstract: A method of treating a patient suffering from asthma which comprises administering to such patient an asthma-relieving amount of a 5-sulphonyl-1,4-dihydropyridine of the formula ##STR1## in which R.sup.1 is aryl having 6 or 10 C atoms, optionally substituted by 1 to 3 identical or different substituents from the group: halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, alkoxycarbonyl (up to 4 C atoms), carboxyl, alkoxy (up to 4 C atoms) or straight-chain or branched alkyl having up to 4 C atoms,or is heteroaryl,R.sup.

Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrines of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic and anti-inflammatory agents.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.12 alkyl, R.sup.2 is C.sub.1 -C.sub.12 alkyl or C.sub.1 -C.sub.4 alkyl which is substituted with halogen, X is halogen, m is 0, 1 or 2 and n is 0, 1 or 2,a process for producing said compound and use thereof as an insecticide acaricide and nematicide.

Abstract: Pyridylaminoethene derivatives of the formula: ##STR1## wherein R.sup.1 is pyridyl, unsubstituted or substituted by one or more substituents R.sup.4 selected from halogen, amino, carboxy, cyano nitro, hydroxy, formyl, trifluoromethyl, aryl, aryloxy, arylthio, benzyloxycarbonylamino, sulphamoyl, tetrazol-5-yl, carbamoyl, thiocarbamoyl, arylcarbamoyl, aroyl, alkyl, alkoxy, alkylthio, alkylsulphonyl, alkylamino, alkylsulphamoyl, arylalkyl, alkanoyl, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbamoyl, alkanoylamino, N-benzyloxycarbonyl-N-alkylamino, or dialkylsulphamoyl, dialkylamino or dialkylcarbamoyl, wherein the alkyl groups may together form a ring, and R.sup.2 and R.sup.3 each represents phenyl, unsubstituted or substituted by one or more substituents R.sup.4 as hereinbefore defined, possess antiarthritic properties.

Abstract: A composition of matter comprising a major part of imidazolidinyl urea and a minor part of pyrithione and/or one or more derivatives of pyrithione is disclosed. The composition exhibits synergistic anti-microbial activity.

Abstract: A salt of formula I or formula II ##STR1## wherein n is 2 or 3 and M is an alkali metal or alkaline earth metal. Such compounds can be used to introduce the metal, e.g. magnesium, ion into cells to cure a deficiency thereof.

Abstract: Selected (1-oxo-2-pyridyl) disulfides are used as active ingredients in animal feed compositions and in methods for increasing the growth and feed efficiency of monogastric animals. A useful new compound of this invention is 2-carboxyphenyl (1-oxo-2-pyridyl) disulfide.

Abstract: 3-Arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, useful as analgesic, anti-rheumatic and anti-inflammatory agents, are prepared by reacting a 3-arylcarbonyl- or 3-cycloalkylcarbonylindole with an aminoalkyl halide in the presence of an acid-acceptor; by reacting a 1-aminoalkyl-1H-indole with an arylcarboxylic acid halide or a cycloalkanecarboxylic acid halide in the presence of a Lewis acid; or by reacting a 3-arylcarbonyl- or 3-cycloalkanecarbonyl-1-tosyloxyalky- or haloalkyl-1H-indole with an amine.

Abstract: The present invention provides a process for the preparation of cystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, melting point 162.degree. C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169.degree. C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.The present invention also provides pharmaceutical compositions containing torasemide of modification I.